Keyphrases
Lenalidomide
100%
Phase II Clinical Trial
100%
T-cell non-Hodgkin Lymphoma
100%
T-cell Lymphoma
66%
Overall Response Rate
33%
Adverse Events
33%
Day Range
33%
Combination Chemotherapy
16%
Improved Outcomes
16%
Disease Progression
16%
Overall Survival
16%
Clinical Activity
16%
Histology
16%
Stable Disease
16%
Novel Therapies
16%
Median Overall Survival
16%
Thrombocytopenia
16%
Progression-free Survival
16%
Partial Response
16%
Multicenter Trial
16%
Interim Analysis
16%
Neutropenia
16%
Anaplastic
16%
Safety Profile
16%
Monotherapy
16%
5-cycle
16%
Median Progression-free Survival
16%
Mycosis Fungoides
16%
Overall Safety
16%
Febrile Neutropenia
16%
Rash
16%
Angioimmunoblastic
16%
Untreated Patients
16%
Two-stage Design
16%
Not Otherwise Specified
16%
Clinical Toxicity
16%
Peripheral T Cells
16%
Response to Therapy
16%
Medicine and Dentistry
Clinical Trial
100%
Lenalidomide
100%
T Cell
100%
Non-Hodgkin Lymphoma
100%
T-Cell Lymphoma
66%
Disease
33%
Adverse Event
33%
Overall Survival
33%
Progression Free Survival
33%
Disease Exacerbation
16%
Thrombocytopenia
16%
Interim Analysis
16%
Monotherapy
16%
Neutropenia
16%
Mycosis fungoides
16%
Combination Chemotherapy
16%
Febrile Neutropenia
16%
Exanthem
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Lenalidomide
100%
Nonhodgkin Lymphoma
100%
T Cell Lymphoma
66%
Disease
33%
Adverse Event
33%
Overall Survival
33%
Progression Free Survival
33%
Chemotherapy
16%
Thrombocytopenia
16%
Disease Exacerbation
16%
Monotherapy
16%
Neutropenia
16%
Mycosis fungoides
16%
Febrile Neutropenia
16%
Rash
16%